Contributions
Abstract: PB2081
Type: Publication Only
Background
Aims
To evaluate the immunophenotypic characteristics of DLBCL and the prognostic significance of specific biomarkers such as bcl2, bcl6, CD 10 and MUM1, in a population-based cohort of patients treated with R-CHOP.
Methods
We performed a retrospective assessment of all cases of DLBCL diagnosed at our institution between 2005-2013. The immunohistochemical expression patterns of all DLBCL patients were analyzed and correlated with the therapeutic response to R-CHOP regimen.
Results
The study included 101 patients diagnosed with DLBCL, with a median age at diagnosis of 57.1 years (19-90 years) and male/female ratio of 1.3/1. Ninety-one patients were eligible for R-CHOP treatment. The median follow-up was 41 months. Out of the 90 cases analyzed by immunohistochemistry CD 10, BCL2, BCL6 and MUM1 expression was found in 17.6%, 50.5%, 72.7% and 81.8% of cases, respectively. Negative expression for CD10, as well as positive expression of BCL2 were adverse prognostic factors for 3-years overall survival (OS) and disease free survival (DFS) (OS for bcl2: 72.3 vs 89.7, p<0.05, OS for CD10: 84.1 vs 75.1, p<0.05). BCL6 and MUM1 expressions, however, did influence neither OS nor DFS.
Conclusion
Session topic: 18. Non-Hodgkin & Hodgkin lymphoma - Biology
Keyword(s): Immunohistochemistry, Diffuse large B cell lymphoma, BCL6, BCL2
Abstract: PB2081
Type: Publication Only
Background
Aims
To evaluate the immunophenotypic characteristics of DLBCL and the prognostic significance of specific biomarkers such as bcl2, bcl6, CD 10 and MUM1, in a population-based cohort of patients treated with R-CHOP.
Methods
We performed a retrospective assessment of all cases of DLBCL diagnosed at our institution between 2005-2013. The immunohistochemical expression patterns of all DLBCL patients were analyzed and correlated with the therapeutic response to R-CHOP regimen.
Results
The study included 101 patients diagnosed with DLBCL, with a median age at diagnosis of 57.1 years (19-90 years) and male/female ratio of 1.3/1. Ninety-one patients were eligible for R-CHOP treatment. The median follow-up was 41 months. Out of the 90 cases analyzed by immunohistochemistry CD 10, BCL2, BCL6 and MUM1 expression was found in 17.6%, 50.5%, 72.7% and 81.8% of cases, respectively. Negative expression for CD10, as well as positive expression of BCL2 were adverse prognostic factors for 3-years overall survival (OS) and disease free survival (DFS) (OS for bcl2: 72.3 vs 89.7, p<0.05, OS for CD10: 84.1 vs 75.1, p<0.05). BCL6 and MUM1 expressions, however, did influence neither OS nor DFS.
Conclusion
Session topic: 18. Non-Hodgkin & Hodgkin lymphoma - Biology
Keyword(s): Immunohistochemistry, Diffuse large B cell lymphoma, BCL6, BCL2